Using two treatments in clinical trials for different cancer types, Decitabine and MEK+BCL-XL blockage, we show their capability to trigger tumor regression in Alb-R26Met mice and to superimpose distinct profiles of immune cell types and immune-checkpoints, impacting immunotherapy response. This evidence concerns the gene BCL2L1 and cancer.